As Consolidation Gathers Steam, Big Pharma Ramps Up India Staffing For The Long Haul
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Multinational drug firms have been down-sizing workforces for cost savings and realigning supply chain issues by consolidating manufacturing units, but the growing importance of emerging markets have led most of them to ramp up recruitment in countries like India
You may also be interested in...
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market
Novartis Designs “Arogya Parivar” To Reach Real India In Its Rural Centers
MUMBAI - Swiss drug maker Novartis recently launched its ace anti-diabetes drug Galvus in India to take Merck's Januvia head on, but the company's larger focus seems to be shifting fast from the mega cities to the rural market where "real India lives.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).